TTP LabTech has been granted a licence for the application of Resonant Acoustic Profiling technology incorporated in the RAP·id 4 instrument in the areas of drug discovery and life sciences by Inverness Medical Switzerland GmbH. TTP LabTech has also acquired the design, manufacturing, and marketing rights to the RAP·id 4 instrument, together with associated sensors and consumables, from Akubio Ltd.
Resonant Acoustic Profiling (RAP) is based on resonant quartz sensor technology optimised for the detection of molecular interactions. By directly detecting molecules bound to the surface of a quartz crystal, the system enables concentration measurement and analysis of the binding events between specific molecules in complex samples that may contain solvents, serum, growth media or other impurities. Currently, few technologies offer life scientists the ability to detect real-time kinetic data of this quality across such a broad range of samples, sample purity and sample concentrations.
RAP·id 4 is a flow-based analysis system which reduces the need to purify samples and generates accurate kinetic, affinity and concentration measurements from complex mixtures, such as blood, serum, cell culture supernatants and periplasmic extracts. A stand-alone, fully automated platform, RAP·id 4 requires minimal user intervention and is controlled via user-friendly software, typically processing an average of 400 samples per day.
See TTP LabTech’s RAP.id 4 at SBS, Booth 921.
Filed Under: Drug Discovery